Diplomat Pharmacy, Inc. (NYSE:DPLO) Releases Earnings Results, Beats Expectations By $0.10 EPS
Diplomat Pharmacy, Inc. (NYSE:DPLO) released its earnings results on Monday. The company reported $0.25 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.15 by $0.10, Briefing.com reports. The firm had revenue of $1.13 billion for the quarter, compared to the consensus estimate of $1.14 billion. Diplomat Pharmacy had a net margin of 0.38% and a return on equity of 7.91%. The company’s revenue was up 3.5% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.23 EPS. Diplomat Pharmacy updated its FY17 guidance to $0.71-0.79 EPS.
Shares of Diplomat Pharmacy (DPLO) traded up 2.97% during mid-day trading on Monday, reaching $15.26. 865,689 shares of the company traded hands. The stock has a market capitalization of $1.02 billion, a PE ratio of 60.80 and a beta of 0.66. The firm has a 50 day moving average of $16.05 and a 200-day moving average of $15.66. Diplomat Pharmacy has a 52 week low of $12.25 and a 52 week high of $38.94.
Several analysts recently commented on DPLO shares. Barclays PLC set a $20.00 price objective on shares of Diplomat Pharmacy and gave the company a “buy” rating in a research report on Tuesday, May 9th. Zacks Investment Research downgraded shares of Diplomat Pharmacy from a “hold” rating to a “sell” rating in a research report on Monday, July 17th. Bank of America Corporation increased their price objective on shares of Diplomat Pharmacy from $17.00 to $18.50 and gave the company a “neutral” rating in a research report on Thursday, May 25th. Mizuho increased their price objective on shares of Diplomat Pharmacy from $17.00 to $19.00 and gave the company a “neutral” rating in a research report on Tuesday, May 16th. Finally, Leerink Swann reissued a “market perform” rating and set a $18.00 price objective (up from $16.00) on shares of Diplomat Pharmacy in a research report on Wednesday, May 17th. Four equities research analysts have rated the stock with a sell rating, eight have assigned a hold rating and two have assigned a buy rating to the stock. The company currently has a consensus rating of “Hold” and an average price target of $20.91.
COPYRIGHT VIOLATION NOTICE: This report was published by American Banking News and is the sole property of of American Banking News. If you are viewing this report on another website, it was copied illegally and reposted in violation of US and international trademark & copyright legislation. The original version of this report can be viewed at https://www.americanbankingnews.com/2017/08/07/diplomat-pharmacy-inc-nysedplo-releases-earnings-results-beats-expectations-by-0-10-eps.html.
Diplomat Pharmacy Company Profile
Diplomat Pharmacy, Inc (Diplomat) operates a specialty pharmacy business, which stocks, dispenses and distributes prescriptions for various biotechnology and specialty pharmaceutical manufacturers. The Company operates through specialty pharmacy services segment. The Company’s primary focus is on medication management programs for individuals with chronic diseases, including oncology, immunology, hepatitis, multiple sclerosis, specialty infusion therapy, and various other serious and/or long-term conditions.
Receive News & Ratings for Diplomat Pharmacy Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Diplomat Pharmacy Inc. and related companies with MarketBeat.com's FREE daily email newsletter.